CRISPR-Cas9 in Cardiovascular Medicine: Unlocking New Potential for Treatment

Cells, Год журнала: 2025, Номер 14(2), С. 131 - 131

Опубликована: Янв. 17, 2025

Cardiovascular diseases (CVDs) remain a significant global health challenge, with many current treatments addressing symptoms rather than the genetic roots of these conditions. The advent CRISPR-Cas9 technology has revolutionized genome editing, offering transformative approach to targeting disease-causing mutations directly. This article examines potential in treatment various CVDs, including atherosclerosis, arrhythmias, cardiomyopathies, hypertension, and Duchenne muscular dystrophy (DMD). technology's ability correct single-gene high precision efficiency positions it as groundbreaking tool cardiovascular therapy. Recent developments have extended capabilities include mitochondrial critical advancement for dysfunctions often linked disorders. Despite its promise, challenges remain, off-target effects, ethical concerns, limitations delivery methods, which hinder translation into clinical practice. also explores regulatory considerations surrounding gene editing technologies, emphasizing implications somatic versus germline modifications. Future research efforts should aim enhance accuracy CRISPR-Cas9, improve systems targeted tissues, ensure safety efficacy long term. Overcoming obstacles could enable not only treat but potentially cure genetically driven diseases, heralding new era medicine health.

Язык: Английский

A highly sensitive MiRNA detection sensor powered by CRISPR/Cas13a and entropy-driven amplification

Bioelectrochemistry, Год журнала: 2025, Номер 165, С. 108992 - 108992

Опубликована: Апрель 23, 2025

Язык: Английский